Peptides DB
Research-centric peptide and protocol reference hub

Desmopressin record · updated 7h ago

Healing & recoverySleep & circadianGrade A · human clinicalResearch use only
All 22 studiesJump to the evidenceCompare
What is Desmopressin used for?

Desmopressin is a synthetic analog of arginine vasopressin (AVP), a hormone that regulates water retention in the body. It primarily acts on the kidneys by binding to V2 receptors in the collecting ducts, promoting the reabsorption of water, which reduces urine output. This mechanism makes desmopressin particularly useful in treating conditions characterized by excessive urination, such as diabetes insipidus and nocturnal enuresis.

How it works: V2 receptor agonist

Primarily researched for · Healing & recoveryRoute · Oral, Subcutaneous injection

Development stage

where Desmopressin sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 120 registered trials. It describes the research record, not a recommendation.

Identity
NameDesmopressin
Chain length—
Molecular weight1,069.2 Da
FormulaC46H64N14O12S2
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 5311065. No verified residue count for this compound.

Pharmacology
MechanismV2 receptor agonist
RouteOral, Subcutaneous injection
Half-life~3-4 hours
Time to peak0.5-1 hour
Duration6-8 hours
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 21, 2026. How this works →
Research stats
Total studies22
Human / animal / cellular15 / 2 / 0
Highest trial phasePhase 4
Years covered2023–2026
Latest study15d ago
Publication history
20232026
Research funding
51 NIH projects · $12.3M awarded · through FY2025
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports3,736
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

22 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Endocrine therapies and hormonal dysfunction after traumatic brain injury: A scoping review.
FindingNot reported in abstract.
review2026Full text read0.80
Wendan Decoction-Derived TMF Alleviates Endolymphatic Hydrops by Modulating the DUSP3/p38 MAPK/AQP2 Axis.
FindingTMF was detected in Wendan Decoction granules at 0.0379% (w/w).
Animal2026Full text read0.70
Factors Affecting the Clinical Response to Desmopressin Treatment for Primary Monosymptomatic Nocturnal Enuresis in Children.
FindingComplete response observed in 346 patients (60.1%) at 3-month follow-up.
Human2023Full text read0.90
Arginine vasopressin deficiency revealing a disseminated human chorionic gonadotropin-secreting germinoma.
FindingNot reported in abstract.
Human2023Full text read0.80
Pregnancy-unmasked latent autoimmune arginine vasopressin deficiency with anti-rabphilin-3a antibody positivity.
FindingNot reported in abstract.
Human2023Full text read0.80
Multifocal intracranial hemorrhage on emergency brain CT in a child with end-stage nephrotic syndrome.
FindingNot reported in abstract.
Human2026Full text read0.80
Ginkgo biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis: A randomized controlled trial.
FindingMedian wet nights per week after 3 months: combination group 0 [IQR 0-2], GBE 6 [0.5-6.5], Desmopressin 2 [0-6], p<0.001.
Human2026Full text read0.80
Evaluation of Ease of Use for Pediatric Medications Requiring Decapsulation, Dissolution, or Partial Dosing: A Questionnaire-Based Study in Japan.
FindingNot reported in abstract.
Human2026Full text read0.80
Von Willebrand Disease Type 2A: An Update.
TakeawayThis review offers an updated synthesis of Type 2A von Willebrand Disease, focusing on its pathophysiology and management but lacks new experimental insights.
review2026Full text read0.90
Efficacy and safety of first-line therapies and first-line-based combination therapies for monosymptomatic nocturnal enuresis in children: a network meta-analysis.
FindingDesmopressin plus oxybutynin, tolterodine, or solifenacin significantly improved CR compared to desmopressin monotherapy.
review2026Full text read0.90
Consensus Recommendations for the Clinical Management of Wolfram syndrome Using a Delphi Method
Finding35 final consensus statements reached ≥80% agreement.
review2026Full text read0.70
Open-Label, Balanced, Randomized, Single-Dose, Three-Treatment, Three-Sequence, Three-Period, Three-Way Crossover Oral Bioequivalence Study of Desmopressin Acetate Oral Solution.
FindingGeometric mean ratio of 101.9% (93.9%-110.5%) for Cmax.
Human2023Full text read0.90

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Desmopressin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Desmopressin is discussed should be drawn from it.

Articles mentioning Desmopressin